| abstract |
The present invention relates to a binding molecule comprising at least one antigen-binding site comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH), said CDR2 amino acid sequence Tyr-Phe -Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Gku-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) and said CDR3 amino acid sequence is Ser-Gly-Pro-Tyr-Ala-Trp -Phe-Asp-Thr (SGPYAWFDT); and may further comprise the hypervariable regions CDR1 ', CDR2' and CDR3 ', said CDR1' having the amino acid sequence Arg-Ala-Ser-Gln-Asn-Gly-Thr-Ser-III Gln (RASQNIGTSIQ), said The CDR2 'amino acid sequence is SerSer-Ser-Glu-Ser-Ile-Ser (SSSESIS) and said CDR3' amino acid sequence is Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT), for example a chimeric humanized an antibody that can be used as a pharmaceutical. SHE |